Sweden, FranceFrance

Cellectis buys Cellartis

16.09.2011

Paris – For €16.4m in cash and roughly €12m in shares, French genome engineering specialist Cellectis has taken over Swedish Cellartis. Cellartis is the European leader in stem cell-derived cardiomyocytes and hepatocytes. With 62 employees, it earned €3.8m in 2010." The acquisition of Cellartis will enable Cellectis to gain a leadership position in the very promising field of stem cells", said Thomas Devedjian, Director and Member of the Executive Committee of the FSI. The FSI or Strategic Investment Fund, is a strategic investment tool of the French State. Together with private investor Pierre Bastid, the FSI will cough up €50m to finance the move. Cellectis wants to become the world leader in stem cell-derived in vitro R&D tools and related technologies. Cellartics value for Celelctis is based on two main pillars. The Swedes own the largest stem cell bank in the world (30 proprietary lines) and in 10 years have built a considerable expertise and two certified production sites in Sweden and Scotland. The second pillar is the research collaborations with partners like Novo Nordisk and the French Blood Agency.

FranceFrance

17.02.2011

Paris/Cambridge (Mass.) – French pharma giant Sanofi-Aventis is set to take-over US biotech specialist Genzyme in a $20.1bn deal, the biggest corporate acquisition worldwide so far this year and the second-largest in the history...

FranceFrance

06.02.2011

Paris – A recently released study provides evidence that there is no reason to believe that omega fatty acids or B vitamins can protect you from severe cardiovascular disease (BMJ, doi: 10.1136/bmj.c6273.). A research group...

FranceFrance

06.02.2011

Nantes – The Nantes University Hospital Institute, also called the “European Center for Transplantation Sciences and Immunotherapy” (TSI-IHU), is commissioning new biomanufacturing capacities. Last year at the site, Atlantic Bio...

FranceFrance

31.01.2011

Bordeaux – A French-Spanish research team has determined that malnutrition with omega-3 fatty acids has deleterious consequences on synaptic functions and emotional behaviours in mice (Nature Neuroscience,...

FranceFrance

04.11.2010

Toulouse – Biopharmaceutical company Cerenis Therapeutics S.A., which is developing drugs based on high density lipoprotein (HDL) to treat cardiovascular diseases, has raised a further a10m in a second close of its third round of...

FranceFrance

04.11.2010

Paris – Genome engineering specialist Cellectis has signed the first licence for the use of induced pluripotent stem (iPS) cells in the development of human regenerative medicines with their inventor Shinya Yamanaka of the Centre...

Displaying results 41 to 50 out of 268

< Previous 41-50 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/4/article/cellectis-buys-cellartis.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • CO.DON3.15 EUR22.1%
  • WILEX3.59 EUR21.3%
  • FORMYCON28.00 EUR21.0%

FLOP

  • CYTOS1.01 CHF-27.9%
  • BIOTEST79.20 EUR-18.1%
  • THERAMETRICS0.07 CHF-12.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.07 EUR-54.8%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 26.04.2015

Current issue

All issues